Cargando…

Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets

A simple, precise, and accurate HPLC method has been developed and validated for the quantitative analysis of Dronedarone Hydrochloride in tablet form. An isocratic separation was achieved using a Waters Symmetry C(8) (100 × 4.6 mm), 5 μm particle size column with a flow rate of 1 ml/min and UV dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabhi, Batuk, Jadeja, Yashwantsinh, Patel, Madhavi, Jebaliya, Hetal, Karia, Denish, Shah, Anamik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617665/
https://www.ncbi.nlm.nih.gov/pubmed/23641332
http://dx.doi.org/10.3797/scipharm.1209-15
_version_ 1782265291425710080
author Dabhi, Batuk
Jadeja, Yashwantsinh
Patel, Madhavi
Jebaliya, Hetal
Karia, Denish
Shah, Anamik
author_facet Dabhi, Batuk
Jadeja, Yashwantsinh
Patel, Madhavi
Jebaliya, Hetal
Karia, Denish
Shah, Anamik
author_sort Dabhi, Batuk
collection PubMed
description A simple, precise, and accurate HPLC method has been developed and validated for the quantitative analysis of Dronedarone Hydrochloride in tablet form. An isocratic separation was achieved using a Waters Symmetry C(8) (100 × 4.6 mm), 5 μm particle size column with a flow rate of 1 ml/min and UV detector at 290 nm. The mobile phase consisted of buffer: methanol (40:60 v/v) (buffer: 50 mM KH(2)PO(4) + 1 ml triethylamine in 1 liter water, pH=2.5 adjusted with ortho-phosphoric acid). The method was validated for specificity, linearity, precision, accuracy, robustness, and solution stability. The specificity of the method was determined by assessing interference from the placebo and by stress testing the drug (forced degradation). The method was linear over the concentration range 20–80 μg/ml (r(2) = 0.999) with a Limit of Detection (LOD) and Limit of Quantitation (LOQ) of 0.1 and 0.3 μg/ml respectively. The accuracy of the method was between 99.2–100.5%. The method was found to be robust and suitable for the quantitative analysis of Dronedarone Hydrochloride in a tablet formulation. Degradation products resulting from the stress studies did not interfere with the detection of Dronedarone Hydrochloride so the assay is thus stability-indicating.
format Online
Article
Text
id pubmed-3617665
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Österreichische Apotheker-Verlagsgesellschaft
record_format MEDLINE/PubMed
spelling pubmed-36176652013-05-02 Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets Dabhi, Batuk Jadeja, Yashwantsinh Patel, Madhavi Jebaliya, Hetal Karia, Denish Shah, Anamik Sci Pharm Research Article A simple, precise, and accurate HPLC method has been developed and validated for the quantitative analysis of Dronedarone Hydrochloride in tablet form. An isocratic separation was achieved using a Waters Symmetry C(8) (100 × 4.6 mm), 5 μm particle size column with a flow rate of 1 ml/min and UV detector at 290 nm. The mobile phase consisted of buffer: methanol (40:60 v/v) (buffer: 50 mM KH(2)PO(4) + 1 ml triethylamine in 1 liter water, pH=2.5 adjusted with ortho-phosphoric acid). The method was validated for specificity, linearity, precision, accuracy, robustness, and solution stability. The specificity of the method was determined by assessing interference from the placebo and by stress testing the drug (forced degradation). The method was linear over the concentration range 20–80 μg/ml (r(2) = 0.999) with a Limit of Detection (LOD) and Limit of Quantitation (LOQ) of 0.1 and 0.3 μg/ml respectively. The accuracy of the method was between 99.2–100.5%. The method was found to be robust and suitable for the quantitative analysis of Dronedarone Hydrochloride in a tablet formulation. Degradation products resulting from the stress studies did not interfere with the detection of Dronedarone Hydrochloride so the assay is thus stability-indicating. Österreichische Apotheker-Verlagsgesellschaft 2013 2012-11-05 /pmc/articles/PMC3617665/ /pubmed/23641332 http://dx.doi.org/10.3797/scipharm.1209-15 Text en © Dabhi et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dabhi, Batuk
Jadeja, Yashwantsinh
Patel, Madhavi
Jebaliya, Hetal
Karia, Denish
Shah, Anamik
Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets
title Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets
title_full Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets
title_fullStr Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets
title_full_unstemmed Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets
title_short Method Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets
title_sort method development and validation of a stability-indicating rp-hplc method for the quantitative analysis of dronedarone hydrochloride in pharmaceutical tablets
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617665/
https://www.ncbi.nlm.nih.gov/pubmed/23641332
http://dx.doi.org/10.3797/scipharm.1209-15
work_keys_str_mv AT dabhibatuk methoddevelopmentandvalidationofastabilityindicatingrphplcmethodforthequantitativeanalysisofdronedaronehydrochlorideinpharmaceuticaltablets
AT jadejayashwantsinh methoddevelopmentandvalidationofastabilityindicatingrphplcmethodforthequantitativeanalysisofdronedaronehydrochlorideinpharmaceuticaltablets
AT patelmadhavi methoddevelopmentandvalidationofastabilityindicatingrphplcmethodforthequantitativeanalysisofdronedaronehydrochlorideinpharmaceuticaltablets
AT jebaliyahetal methoddevelopmentandvalidationofastabilityindicatingrphplcmethodforthequantitativeanalysisofdronedaronehydrochlorideinpharmaceuticaltablets
AT kariadenish methoddevelopmentandvalidationofastabilityindicatingrphplcmethodforthequantitativeanalysisofdronedaronehydrochlorideinpharmaceuticaltablets
AT shahanamik methoddevelopmentandvalidationofastabilityindicatingrphplcmethodforthequantitativeanalysisofdronedaronehydrochlorideinpharmaceuticaltablets